New momentum in the digital technology market. PYC Therapeutics has announced its intention to work with Google Cloud and other specialized partners to develop machine learning models that create a new generation of precision medicine, After an initial investment of ten million dollarsThe project is required to be developed over a period of twelve months.
Specifically, the project will seek to leverage the company’s patent drug data to predict the optimal sequence and structure of new drugs. This is all information will be stored on the Google Cloud Artificial Intelligence (AI) platform. From the company they assure that “the project maintains a strong integration between computational (in silico) and biological (in vitro) parameters for the discovery of new drugs.”
Other specialized partners in collaboration will be, Those who will participate for an initial fee of $4.5 million, as they will be able to access PYC’s proprietary data sets and capabilities. It includes GoPomelo, Pte LD and a special purpose vehicle expressly created for the implementation of the project.
There will be other exclusive partners in the collaboration, who will participate for an initial fee of $4.5 million.
Within this agreement, Google will benefit from retaining the right to publish the process used to design, host and run the machine learning models used by the company’s deployed artificial intelligence platforms. PYC adds that it will finance “projects with existing working capital reserves”..
PYC Therapeutics is a clinical-stage biotechnology company that develops and delivers innovative RNA therapies to improve the lives of patients with genetic diseases. Specifically, the company It uses its proprietary drug delivery platform to improve its precision medicinesEspecially in programs that consider monogenetic diseases.
In August 2023, Grifols announced an agreement with Google Cloud to promote artificial intelligence technology and accelerate the development of new biopharmaceutical drugs. The agreement included new technologies, rapid prototype testing and rapid scaling. from The Catalan company also thought that revitalizing internal processes would help improve the teams’ agility.
In particular, Google has developed two tools to improve drug development through AI. is the first Target and Lead Identification Suite, designed to predict and understand the structure of drugs. Another tool is called Multiomics SuiteResponsible for directing, storing, analyzing and sharing high volumes of genomic data.
